Edition:
United Kingdom

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

104.10USD
18 Mar 2019
Change (% chg)

$2.86 (+2.82%)
Prev Close
$101.24
Open
$101.21
Day's High
$104.22
Day's Low
$101.09
Volume
17,066
Avg. Vol
99,690
52-wk High
$127.74
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals Q1 Earnings Per Share $1.25
Wednesday, 6 Feb 2019 

Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER AND THREE MONTHS ENDED DECEMBER 31, 2018.Q1 EARNINGS PER SHARE $1.25.Q1 EARNINGS PER SHARE ESTIMATE $1.35 -- REFINITIV IBES DATA.Q1 REVENUE $69.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71.3 MILLION.ENANTA PHARMACEUTICALS - RESEARCH AND DEVELOPMENT PROGRAMS PROGRESSING "WELL" WITH CLINICAL MILESTONES EXPECTED IN 2019 IN OUR RSV, NASH, AND HBV PROGRAMS.CASH AND MARKETABLE SECURITIES TOTALED $357.3 MILLION AT DECEMBER 31, 2018.  Full Article

Enanta Pharmaceuticals Sees HCV Royalty Revenue Of $191.6 Mln In Fiscal 2018
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2019 DURING THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - SEES HCV ROYALTY REVENUE OF $191.6 MILLION IN FISCAL 2018.ENANTA PHARMACEUTICALS INC - TOPLINE PHASE 2 RSV CHALLENGE STUDY DATA NOW ANTICIPATED MID-2019.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF HBV CORE INHIBITOR EDP-514 PLANNED TO BEGIN SECOND HALF OF 2019.ENANTA PHARMACEUTICALS INC - EXPECTS TO IDENTIFY AN FXR FOLLOW-ON CLINICAL CANDIDATE IN 2019.  Full Article

Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61
Tuesday, 8 May 2018 

May 8 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018.Q2 EARNINGS PER SHARE $0.61.Q2 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S.ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MILLION DUE TO INCREASE IN ABBVIE'S MAVYRET SALES.QTRLY TOTAL REVENUE WAS $44.0 MILLION, COMPARED TO $9.0 MILLION.  Full Article

Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED.ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY "INTREPID" OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED.ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

Enanta Pharma Q4 earnings per share $1.86
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article